Patents by Inventor Patrick Johnson
Patrick Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260125960Abstract: A tong assembly for use in the make up or breakout of a threaded connection between adjacent tubulars in a tubular string includes jaws that engage the tubulars, handles for rotating the jaws, and a actuation assembly for exerting a force to the handles. The actuation assembly applies the force to the handles along a path intersecting the handles, which avoids creating torsion in the handles. The connection between the actuation assembly and the handles includes trunnion assemblies that swivel about ends of the handles to align the force with the handles.Type: ApplicationFiled: November 4, 2024Publication date: May 7, 2026Applicant: Petol Gearench Division of Orbix CorporationInventors: Patrick Johnson, Ben Stenmark
-
Patent number: 12458695Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: GrantFiled: February 14, 2025Date of Patent: November 4, 2025Assignee: Apellis Pharmaceuticals, Inc.Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Publication number: 20250170209Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: ApplicationFiled: February 14, 2025Publication date: May 29, 2025Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Publication number: 20250170210Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: ApplicationFiled: February 14, 2025Publication date: May 29, 2025Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Patent number: 12290566Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: GrantFiled: February 28, 2023Date of Patent: May 6, 2025Assignee: Apellis Pharmaceuticals, Inc.Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Publication number: 20240285783Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: ApplicationFiled: November 2, 2023Publication date: August 29, 2024Applicant: Apellis Pharmaceuticals, Inc.Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Patent number: 12065429Abstract: The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g., dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: GrantFiled: December 1, 2023Date of Patent: August 20, 2024Assignee: Leo Pharma A/SInventors: Mark Andrews, Mogens Larsen, Alan Jessiman, Patrick Johnson, Kevin Neil Dack
-
Publication number: 20240208938Abstract: The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g., dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: ApplicationFiled: December 1, 2023Publication date: June 27, 2024Inventors: Mark ANDREWS, Mogens LARSEN, Alan JESSIMAN, Patrick JOHNSON, Kevin Neil DACK
-
Publication number: 20240115655Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: ApplicationFiled: February 28, 2023Publication date: April 11, 2024Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Patent number: 11844841Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: GrantFiled: April 29, 2021Date of Patent: December 19, 2023Assignee: Apellis Pharmaceuticals, Inc.Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Patent number: 11731875Abstract: Methods for producing graphene oxide products are disclosed. In one embodiment, a method of producing a graphene oxide product includes contacting a carbon-containing feedstock with an oxidizing composition comprising aqueous nitric acid, wherein the concentration of nitric acid is 50 to 63 wt %, to from a reactant slurry, in response to the contacting step, oxidizing the carbon-containing feedstock of the reactant slurry to form a graphite oxide slurry; and processing the graphite oxide slurry into a graphene oxide product.Type: GrantFiled: January 14, 2021Date of Patent: August 22, 2023Assignee: UNIVERSITY OF WYOMINGInventors: Patrick Johnson, Ana Paula Martins Leandro
-
Publication number: 20220280598Abstract: Methods and compositions for inhibiting complement are described.Type: ApplicationFiled: July 17, 2020Publication date: September 8, 2022Inventors: Pascal Deschatelets, Cedric Francois, Federico Grossi, Patrick Johnson, Lukas Scheibler
-
Patent number: 11434734Abstract: A sucker rod transfer assembly for handling a sucker rod prior to the sucker rod being installed for use in a well. The transfer assembly includes an elongated body having a cavity that receives an end of the sucker rod. A slot is formed in an end wall of the body, and an opening extends lengthwise along the body that exposes the cavity. The sucker rod is engaged with the transfer assembly by inserting a tip and shoulder of the sucker rod laterally into the opening while sliding a portion of the sucker rod below the shoulder into the slot. The sucker rod is axially supported in the transfer assembly by interfering contact between the shoulder and edges of the slot. A spring selectively biases safety rings around the sucker rod end to retain the sucker rod end in the cavity.Type: GrantFiled: April 15, 2021Date of Patent: September 6, 2022Assignee: PETOL GEARENCH DIVISION OF ORBIX CORPORATIONInventors: Ben Stenmark, Patrick Johnson, Greg Burbach
-
Publication number: 20220227894Abstract: A chitosan based coating system. The coating system includes a carrier agent and a chitosan based agent preservative. The carrier agent may be a cleaning agent, a polishing agent, and/or a finishing agent. The chitosan based agent may be a chitosan acetate and salts thereof, chitosan citrate acetate and salts thereof, or combinations thereof. The coating system may include 0.01-5 weight percent chitosan based agent. The chitosan based agent functions as a preservative to increase both the shelf-life and use-life of the coating system as well as functions as a chelating agent to reduce soap scum.Type: ApplicationFiled: May 18, 2020Publication date: July 21, 2022Inventors: John F Schierlmann, Patrick Johnson, Pietrina Peshel, Erica Walker, Charles Johnson
-
Publication number: 20210401997Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: ApplicationFiled: April 29, 2021Publication date: December 30, 2021Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Publication number: 20210214231Abstract: Methods for producing graphene oxide products are disclosed. In one embodiment, a method of producing a graphene oxide product includes contacting a carbon-containing feedstock with an oxidizing composition comprising aqueous nitric acid, wherein the concentration of nitric acid is 50 to 63 wt %, to from a reactant slurry, in response to the contacting step, oxidizing the carbon-containing feedstock of the reactant slurry to form a graphite oxide slurry; and processing the graphite oxide slurry into a graphene oxide product.Type: ApplicationFiled: January 14, 2021Publication date: July 15, 2021Applicant: UNIVERSITY OF WYOMINGInventors: Patrick JOHNSON, Ana Paula MARTINS LEANDRO
-
Patent number: 11040107Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: GrantFiled: April 9, 2018Date of Patent: June 22, 2021Assignee: Apellis Pharmaceuticals, Inc.Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Patent number: 11037108Abstract: A method for facilitating a wireless transaction includes receiving, by a transaction fulfillment system, a transaction request from a transaction requester and verifying an identity of the transaction requester. After verifying the identity of the transaction requester, a transaction code is communicated from the transaction fulfillment system to a wireless communication device. After receiving the transaction code, the transaction code is optically scanned from a visual display of the wireless communication device by the transaction fulfillment system.Type: GrantFiled: October 3, 2017Date of Patent: June 15, 2021Assignee: Aeritas, LLCInventors: Malik Mamdani, Curtis Grant, Patrick Johnson, Kevin Bomar, Tim Whatley
-
Patent number: D1042497Type: GrantFiled: June 27, 2022Date of Patent: September 17, 2024Assignee: Fifth Third BankInventors: Shanna Anderson, Heather R. Bowling, Katrina Rothan, Sandeep M. Basavarajaiah, Saikrishna Kondapally, Alexa Jo Hojczyk, George Edwin McLaughlin, III, Yaswanth Krishna Panchangam, Shawn T. Niehaus, Michael L. Butera, Nathan Douglas Smith, Jason Warner, Joseph Humphries, Patrick Johnson
-
Patent number: D1053221Type: GrantFiled: August 2, 2022Date of Patent: December 3, 2024Assignee: Petol Gearench Division of Orbix CorporationInventors: Patrick Johnson, Ben Stenmark, Greg Burbach